These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35584002)

  • 1. Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension.
    Westgate CSJ; Markey K; Mitchell JL; Yiangou A; Singhal R; Stewart P; Tomlinson JW; Lavery GG; Mollan SP; Sinclair AJ
    Eur J Endocrinol; 2022 Aug; 187(2):323-333. PubMed ID: 35584002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation?
    Sinclair AJ; Walker EA; Burdon MA; van Beek AP; Kema IP; Hughes BA; Murray PI; Nightingale PG; Stewart PM; Rauz S; Tomlinson JW
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5348-56. PubMed ID: 20826586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT).
    Woods CP; Corrigan M; Gathercole L; Taylor A; Hughes B; Gaoatswe G; Manolopoulos K; Hogan AE; O'Connell J; Stewart PM; Tomlinson JW; O'Shea D; Sherlock M
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1434-44. PubMed ID: 25603461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.
    Tomlinson JW; Sherlock M; Hughes B; Hughes SV; Kilvington F; Bartlett W; Courtney R; Rejto P; Carley W; Stewart PM
    J Clin Endocrinol Metab; 2007 Mar; 92(3):857-64. PubMed ID: 17200165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
    Masuzaki H; Flier JS
    Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
    Morton NM; Seckl JR
    Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
    Hardy RS; Botfield H; Markey K; Mitchell JL; Alimajstorovic Z; Westgate CSJ; Sagmeister M; Fairclough RJ; Ottridge RS; Yiangou A; Storbeck KH; Taylor AE; Gilligan LC; Arlt W; Stewart PM; Tomlinson JW; Mollan SP; Lavery GG; Sinclair AJ
    J Clin Endocrinol Metab; 2021 Jan; 106(1):174-187. PubMed ID: 33098644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased central adiposity and decreased subcutaneous adipose tissue 11β-hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose tolerance-A longitudinal cohort study.
    Crowley RK; Woods CP; Hughes BA; Gray J; McCarthy T; Taylor AE; Gathercole LL; Shackleton CHL; Crabtree N; Arlt W; Stewart PM; Tomlinson JW
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):72-81. PubMed ID: 30667079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
    Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
    Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin A decreases pre-receptor amplification of glucocorticoids in obesity: study on the effect of vitamin A on 11beta-hydroxysteroid dehydrogenase type 1 activity in liver and visceral fat of WNIN/Ob obese rats.
    Sakamuri VP; Ananthathmakula P; Veettil GN; Ayyalasomayajula V
    Nutr J; 2011 Jun; 10():70. PubMed ID: 21696642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
    Walker BR
    Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.
    Baudrand R; Carvajal CA; Riquelme A; Morales M; Solis N; Pizarro M; Escalona A; Boza C; Pérez G; Domínguez A; Arrese M; Fardella CE
    Obes Surg; 2010 Jan; 20(1):77-83. PubMed ID: 19690925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7-oxysterols modulate glucocorticoid activity in adipocytes through competition for 11beta-hydroxysteroid dehydrogenase type.
    Wamil M; Andrew R; Chapman KE; Street J; Morton NM; Seckl JR
    Endocrinology; 2008 Dec; 149(12):5909-18. PubMed ID: 18755798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5alpha-reductase activity.
    Tomlinson JW; Finney J; Gay C; Hughes BA; Hughes SV; Stewart PM
    Diabetes; 2008 Oct; 57(10):2652-60. PubMed ID: 18633104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M; Seckl JR
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertical sleeve gastrectomy normalizes circulating glucocorticoid levels and lowers glucocorticoid action tissue-selectively in mice.
    Akalestou E; Lopez-Noriega L; Christakis I; Hu M; Miras AD; Leclerc I; Rutter GA
    Front Endocrinol (Lausanne); 2022; 13():1020576. PubMed ID: 36246869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
    Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
    Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
    Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
    Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of Hsd11b1 suppresses caloric restriction-induced bone marrow adiposity in male but not female mice.
    Lovdel A; Suchacki KJ; Roberts F; Sulston RJ; Wallace RJ; Thomas BJ; Bell RMB; Pruñonosa Cervera I; Macpherson GJ; Morton NM; Homer NZM; Chapman KE; Cawthorn WP
    J Endocrinol; 2024 Aug; 262(2):. PubMed ID: 38805506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH; Walker BR
    Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.